Dementia and survival in Parkinson disease - A 12-year population study

被引:319
作者
Buter, T. C. [1 ]
van den Hout, A. [3 ]
Matthews, F. E. [3 ]
Larsen, J. P. [1 ,2 ]
Brayne, C. [4 ]
Aarsland, D. [1 ,2 ]
机构
[1] Stavanger Univ Hosp, Sect Geriatr Psychiat, Ctr Movement Disorders, N-4095 Stavanger, Norway
[2] Univ Bergen, Inst Clin Med, N-5020 Bergen, Norway
[3] Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 1TN, England
[4] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 1TN, England
基金
英国医学研究理事会;
关键词
D O I
10.1212/01.wnl.0000306632.43729.24
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The risk for dementia in Parkinson disease (PD) is high, with important clinical consequences for patients with PD. However, the absolute risk of dementia and how it affects survival in PD are not known. Such questions are important for patients, their families, and service providers but require long-term studies. Methods: This study is a prospective longitudinal cohort study with patients from a prevalence study of PD in Norway. Patients were reassessed 4, 8, 9, 10, 11, and 12 years after prevalence day. A dementia diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, criteria was based on a semistructured caregiver interview, cognitive rating scales, and neuropsychological tests. Progression from PD to PD with dementia and death was modeled using a continuous-time three-state irreversible Markov model. Results: A total of 233 PD patients were included, and 140 patients (60%, 95% CI 54% to 66%) had developed dementia by the end of the study period. The cumulative incidence of dementia steadily increases with age and duration of PD and, conditional on survival, increases to 80% to 90% by age 90 years. Women live with PD longer than men and spend more years with dementia. At age 70 years, a man with PD but no dementia has a life expectancy of 8 years, of which 5 years would be expected to be dementia free and 3 years would be expected to be with dementia. Conclusion: Dementia is a key part of survival in Parkinson disease and must be planned for in services for this condition.
引用
收藏
页码:1017 / 1022
页数:6
相关论文
共 41 条
  • [1] The effect of age of onset of PD on risk of dementia
    Aarsland, D.
    Kvaloy, J. T.
    Andersen, K.
    Larsen, J. P.
    Tang, M. X.
    Lolk, A.
    Kragh-Sorensen, P.
    Marder, K.
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 (01) : 38 - 45
  • [2] Neuropathology of dementia in Parkinson's disease: A prospective, community-based study
    Aarsland, D
    Perry, R
    Brown, A
    Larsen, JP
    Ballard, C
    [J]. ANNALS OF NEUROLOGY, 2005, 58 (05) : 773 - 776
  • [3] A systematic review of prevalence studies of dementia in Parkinson's disease
    Aarsland, D
    Zaccai, J
    Brayne, C
    [J]. MOVEMENT DISORDERS, 2005, 20 (10) : 1255 - 1263
  • [4] Risk of dementia in Parkinson's disease - A community-based, prospective study
    Aarsland, D
    Andersen, K
    Larsen, JP
    Lolk, A
    Nielsen, H
    Kragh-Sorensen, P
    [J]. NEUROLOGY, 2001, 56 (06) : 730 - 736
  • [5] Prevalence and characteristics of dementia in Parkinson disease - An 8-year prospective study
    Aarsland, D
    Andersen, K
    Larsen, JP
    Lolk, A
    Kragh-Sorensen, P
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (03) : 387 - 392
  • [6] Frequency of dementia in Parkinson disease
    Aarsland, D
    Tandberg, E
    Larsen, JP
    Cummings, JL
    [J]. ARCHIVES OF NEUROLOGY, 1996, 53 (06) : 538 - 542
  • [7] Aarsland D, 1999, INT J GERIATR PSYCH, V14, P866, DOI 10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.3.CO
  • [8] 2-Q
  • [9] Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress
    Aarsland, D.
    Bronnick, K.
    Ehrt, U.
    De Deyn, P. P.
    Tekin, S.
    Emre, M.
    Cummings, J. L.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (01) : 36 - 42
  • [10] Prevalence of dementia in the elderly in Europe
    Berr, C
    Wancata, J
    Ritchie, K
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (04) : 463 - 471